KalVista Q1 2023 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2022. Research and development expenses increased to $18.2 million, and general and administrative expenses rose to $8.1 million. The net loss for the quarter was $23.0 million, or $(0.94) per share. Cash, cash equivalents, and marketable securities totaled $142.1 million as of July 31, 2022.
KVD824 KOMPLETE Phase 2 clinical trial reached 50% enrollment milestone.
KONFIDENT-S open label extension study was initiated for sebetralstat.
Enrollment is proceeding as expected for the Phase 3 KONFIDENT trial for sebetralstat, with data expected in the second half of 2023.
The Phase 2 KOMPLETE clinical trial for KVD824 also remains on track with its enrollment targets, with data expected in mid-2023.
KalVista
KalVista
Forward Guidance
The press release contains forward-looking statements regarding the timing and outcomes of clinical trials, the safety and efficacy of product candidates, and the ability to obtain regulatory approvals.